GaryMeiningerMD

PubMed

• 1 citations
  Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study.
  Zhong Yuan, Frank J. DeFalco, Lu Wang, Laura Hester, James Weaver, Joel N. Swerdel, Amy Freedman, Patrick B. Ryan, Martijn J. Schuemie, Rose Qiu, Jacqueline Yee, Gary ...> ;Current Medical Research and Opinion. 2020 May 14
• 25 citations
  Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational ...
  Lu Wang, Erica A. Voss, James Weaver, Laura Hester, Zhong Yuan, Frank J. DeFalco, Martijn J. Schuemie, Patrick B. Ryan, Don Sun, Amy Freedman, Maria Alba, Joan Lind, G...> ;Pharmacoepidemiology and Drug Safety. 2019 Aug 27
• 2997 citations
  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
  Vlado Perkovic, Meg Jardine, Bruce Neal, Severine Bompoint, Hiddo J.L. Heerspink, David M. Charytan, Robert Edwards, Rajiv Agarwal, George L. Bakris, Scott Bull, Chris...> ;The New England Journal of Medicine. 2019 Apr 14
• 5 citations
  Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.
  Derek J. Nunez, Myriam Alexander, Laura M. Yerges-Armstrong, Gurparkash Singh, Geert Byttebier, Elisa Fabbrini, Dawn Waterworth, Gary Meininger, Nicholas Galwey, Lars ...> ;American Journal of Physiology. Gastrointestinal and Liver Physiology. 2019 Mar 1
• 6 citations
  Achieving the composite endpoint of HbA1c, body weight, and systolic blood pressure reduction with canagliflozin in patients with type 2 diabetes.
  Katherine Merton, Michael J. Davies, Ujjwala Vijapurkar, Doreen Inman, Gary Meininger> ;Current Medical Research and Opinion. 2018 Feb 1
• 265 citations
  Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R) : A randomized, placebo-controlled trial
  Bruce Neal, Vlado Perkovic, David R. Matthews, Kenneth W. Mahaffey, Greg Fulcher, Gary Meininger, Ngozi Erondu, Mehul Desai, Wayne Shaw, Frank Vercruysse, Jacqueline Y...> ;Diabetes, Obesity & Metabolism. 2017 Mar 1
• 25 citations
  Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis
  Rong Qiu, Dainius Balis, John Xie, Michael J. Davies, Mehul Desai, Gary Meininger> ;Current Medical Research and Opinion. 2017 Jan 4
• 238 citations
  Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
  Hiddo J.L. Heerspink, Mehul Desai, Meg Jardine, Dainius Balis, Gary Meininger, Vlado Perkovic> ;Journal of the American Society of Nephrology. 2017 Jan 1
• 8 citations
  Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.
  David R. Matthews, B. Zinman, Cindy Tong, Gary Meininger, David Polidori> ;Diabetic Medicine. 2016 Dec 1
• 4 citations
  Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes
  Rong Qiu, Dainius Balis, George Capuano, John Xie, Gary Meininger> ;Diabetes Therapy. 2016 Oct 12
• 6 citations
  A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
  Charmi Patel, Robert A. Bailey, Ujjwala Vijapurkar, Gary Meininger, Lawrence Blonde> ;BMC Health Services Research. 2016 Aug 5
• 14 citations
  Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies
  Richard E. Gilbert, Matthew R. Weir, Paola Fioretto, Gordon Law, Mehul Desai, Irina Kline, Wayne Shaw, Gary Meininger> ;Canadian Journal of Diabetes. 2016 Jun 1
• 14 citations
  Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India
  Kiran Kumar, Viswanathan Mohan, Bipin Sethi, Pramod Gandhi, Ganapathi Bantwal, John Xie, Gary Meininger, Rong Qiu> ;Indian Journal of Endocrinology and Metabolism. 2016 May 1
• 7 citations
  Efficacy and Safety of Canagliflozin in Type 2 Diabetes Patients of Different Ethnicity
  Jaime A. Davidson, Richard Aguilar, Fernando J. Lavalle Gonzalez, Angelina Trujillo, Maria Alba, Ujjwala Vijapurkar, Gary Meininger> ;Ethnicity & Disease. 2016 Apr 21
• 47 citations
  Efficacy and Safety of Canagliflozin in Individuals Aged 75 and Older with Type 2 Diabetes Mellitus: A Pooled Analysis.
  Alan J. Sinclair, Bruce Bode, Stewart B. Harris, Ujjwala Vijapurkar, Wayne Shaw, Mehul Desai, Gary Meininger> ;Journal of the American Geriatrics Society. 2016 Mar 1
• 54 citations
  Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
  Lawrence Blonde, Kaj Stenlöf, Albert Fung, John Xie, William Canovatchel, Gary Meininger> ;Postgraduate Medicine. 2016 Apr 7
• 65 citations
  Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes
  Greg Fulcher, David R. Matthews, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Chantal Mathieu, Vincent Woo, Carol Wysham, George Capuano, Mehul Desai, Wayne Sha...> ;Diabetes, Obesity & Metabolism. 2016 Jan 1
• Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
  Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger> ;Diabetes Care. 2016 Jan 1
• 291 citations
  Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
  Nelson B. Watts, John P. Bilezikian, Keith Usiskin, Robert Edwards, Mehul Desai, Gordon Law, Gary Meininger> ;The Journal of Clinical Endocrinology and Metabolism. 2016 Jan 1
• 76 citations
  Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
  Norm Rosenthal, Gary Meininger, Kirk Ways, David Polidori, Mehul Desai, Rong Qiu, Maria Alba, Frank Vercruysse, Dainius Balis, Wayne Shaw, Robert Edwards, Scott Bull, ...> ;Annals of the New York Academy of Sciences. 2015 Nov 1
• 39 citations
  Renal effects of canagliflozin in type 2 diabetes mellitus
  Vlado Perkovic, Meg Jardine, Ujjwala Vijapurkar, Gary Meininger> ;Current Medical Research and Opinion. 2015 Oct 23
• 9 citations
  Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trials
  Lawrence Blonde, Vincent Woo, Chantal Mathieu, Jacqueline Yee, Ujjwala Vijapurkar, William Canovatchel, Gary Meininger> ;Current Medical Research and Opinion. 2015 Aug 20
• 222 citations
  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
  Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger> ;Diabetes Care. 2015 Sep 1
• 15 citations
  The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus
  James R. Gavin, Melanie J. Davies, Michael J. Davies, Ujjwala Vijapurkar, Maria Alba, Gary Meininger> ;Current Medical Research and Opinion. 2015 Jun 29
• 34 citations
  Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
  Greg Fulcher, David R. Matthews, Vlado Perkovic, Dick de Zeeuw, Kenneth W. Mahaffey, Robert Weiss, Julio Rosenstock, George Capuano, Mehul Desai, Wayne Shaw, Frank Ver...> ;Diabetes Therapy. 2015 Jun 17
• Join now to see all

Journal Articles

• Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India  
  K. M. Prasanna Kumar, Viswanathan Mohan, Bipin Sethi, Pramod Gandhi, Ganapathi Bantwal, John Xie, Gary Meininger, Rong Qiu, Indian Journal of Endocrinology and Metabolism, 4/2016
• Canagliflozin for the treatment of adults with Type 2 diabetes  
  Meininger G, Canovatchel W, Polidori D, Rosenthal N, Diabetes Management, 2015